{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:15:18Z","timestamp":1707524118990},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,7]]},"DOI":"10.7759\/cureus.10299","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T18:33:31Z","timestamp":1599503611000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Kara","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mena","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Al-Ourani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Etiology of acute pancreatitis","volume":"9","author":"Gimenez TR","year":"2014","unstructured":"Gimenez TR, Calvo AG, Vicent JG. Etiology of acute pancreatitis. Centr Eur J Med. 2014, 9:530-542.","journal-title":"Centr Eur J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200411000-00010","article-title":"Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis","volume":"328","author":"Iskandar SB","year":"2004","unstructured":"Iskandar SB, Olive KE. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci. 2004, 328:290-294. 10.1097\/00000441-200411000-00010","journal-title":"Am J Med Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7027","article-title":"Acute pancreatitis due to disseminated varicella zoster infection in an individual with newly diagnosed human immunodeficiency virus","volume":"12","author":"Roy S","year":"2020","unstructured":"Roy S, Bose S, Pandey RK, Naramala S, Hossain MR. Acute pancreatitis due to disseminated varicella zoster infection in an individual with newly diagnosed human immunodeficiency virus. Cureus. 2020, 12:7027. 10.7759\/cureus.7027","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.261","article-title":"Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis","volume":"110","author":"Nawaz H","year":"2015","unstructured":"Nawaz H, Koutroumpakis E, Easler J, et al.. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015, 110:1497-1503. 10.1038\/ajg.2015.261","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01633.x","article-title":"Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance","volume":"259","author":"Eriksson JG","year":"2006","unstructured":"Eriksson JG, Lehtovirta M, Ehrnstrom B, Salmela S, Groop L. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. J Intern Med. 2006, 259:553-560. 10.1111\/j.1365-2796.2006.01633.x","journal-title":"J Intern Med"},{"key":"ref6","article-title":"Insulin lispro (Humalog), the first marketed insulin analogue: indications, contraindications and need for further studies","volume":"158","author":"Puttagunta AL","year":"1998","unstructured":"Puttagunta AL, Toth EL. Insulin lispro (Humalog), the first marketed insulin analogue: indications, contraindications and need for further studies. CMAJ. 1998, 158:506-511.","journal-title":"CMAJ"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1007\/BF00542203","article-title":"Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects","volume":"24","author":"Rossner S","year":"1983","unstructured":"Rossner S, Weiner L. Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects. Eur J Clin Pharmacol. 1983, 24:573-577.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.3109\/00365528909091255","article-title":"The clinical safety of omeprazole","volume":"24","author":"S\u00f6lvell L","year":"1989","unstructured":"S\u00f6lvell L. The clinical safety of omeprazole. Scand J Gastroenterol. 1989, 24:","journal-title":"Scand J Gastroenterol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2036.1997.136312000.x","article-title":"The safety of ranitidine in over a decade of use","volume":"11","author":"Mills JG","year":"1997","unstructured":"Mills JG, Koch KM, Webster C, Sirgo MA, Fitzgerald K, Wood JR. The safety of ranitidine in over a decade of use. Aliment Pharmacol Ther. 1997, 11:129-137.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12659\/ajcr.903327","article-title":"Medication as a cause of acute pancreatitis","volume":"18","author":"Ghatak R","year":"2017","unstructured":"Ghatak R, Masso L, Kapadia D, Kulairi ZI. Medication as a cause of acute pancreatitis. Am J Case Rep. 2017, 18:839-841. 10.12659\/ajcr.903327","journal-title":"Am J Case Rep"},{"key":"ref11","article-title":"Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients","volume":"108","author":"Durrington PN","year":"1982","unstructured":"Durrington PN, Cairns SA. Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients. Ann Intern Med. 1982, 108:567-568.","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-108-4-567","article-title":"Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients","volume":"108","author":"Socinski M","year":"1988","unstructured":"Socinski M, Garnick MB. Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients. Ann Intern Med. 1988, 108:567-568.","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2077-1","article-title":"Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience","volume":"93","author":"Garcia-Noblejas A","year":"2014","unstructured":"Garcia-Noblejas A, Martinez Chamorro C, Navarro Matilla B, et al.. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. Ann Hematol. 2014, 93:1551-1558. 10.1007\/s00277-014-2077-1","journal-title":"Ann Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1046862","article-title":"Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study","volume":"57","author":"Gafter-Gvili A","year":"2016","unstructured":"Gafter-Gvili A, Ribakovsky E, Mizrahi N, et al.. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma. 2016, 57:63-69. 10.3109\/10428194.2015.1046862","journal-title":"Leuk Lymphoma"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks K","year":"2015","unstructured":"Maddocks K, Christian B, Jaglowski S, et al.. A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma. Blood. 2015, 125:242-248. 10.1182\/blood-2014-08-597914","journal-title":"Blood"},{"key":"ref16","article-title":"Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective","volume":"16","author":"Kasi PM","year":"2012","unstructured":"Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective. Crit Care. 2012, 16:231.","journal-title":"Crit Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels MCA","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, et al.. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015, 16:704-715. 10.1016\/s1470-2045(15)70128-2","journal-title":"Lancet Oncol"},{"key":"ref18","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study","volume":"130","author":"Sehn LH","year":"2017","unstructured":"Sehn LH, Herrera AF, Matasar MJ, et al.. Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study. Blood. 2017, 130:2821-2822.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly H","year":"2019","unstructured":"Tilly H, Morschhauser F, Bartlett NL, et al.. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019, 20:998-1010. 10.1016\/s1470-2045(19)30091-9","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1053","article-title":"Acute pancreatitis in immunocompromised patients: beware of varicella zoster virus primo-infection","volume":"5","author":"Picod A","year":"2017","unstructured":"Picod A, Corre E, Maury E, Duriez P, Hoyeau N, Coppo P. Acute pancreatitis in immunocompromised patients: beware of varicella zoster virus primo-infection. Clin Case Rep. 2017, 5:1261-1263. 10.1002\/ccr3.1053","journal-title":"Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/38765-acute-pancreatitis-induced-by-polatuzumab-vedotin-piiq-in-combination-with-bendamustine-and-rituximab-for-diffuse-large-b-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:03Z","timestamp":1707506763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/38765-acute-pancreatitis-induced-by-polatuzumab-vedotin-piiq-in-combination-with-bendamustine-and-rituximab-for-diffuse-large-b-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.10299","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,7]]}}}